| Nov 16 |
Granite Point Capital’s Returns, AUM, and Holdings |
| Nov 15 |
Raymond James likes Galapagos in premarket analyst action |
| Nov 15 |
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results |
| Nov 14 |
Ovid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27 |
| Nov 8 |
Ovid Therapeutics reports Q3 results |
| Nov 8 |
Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress |
| Oct 31 |
The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut |
| Oct 25 |
Ovid to host CC on new data on OV101 in Angelman syndrome |
| Oct 25 |
Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting |
| Oct 22 |
Ovid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community |
| Oct 22 |
Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT |
| Oct 19 |
Key events next week - healthcare |
| Sep 24 |
Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies |
| Sep 19 |
Ovid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018 |
| Sep 6 |
Ovid Therapeutics (OVID) Presents At Baird's Global Healthcare Conference - Slideshow |
| Sep 5 |
OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy? |
| Sep 4 |
Ovid Therapeutics CFO to depart September 21 |
| Sep 4 |
Dr. Yaron Werber, Chief Business and Financial Officer, to Return to Wall Street |
| Aug 29 |
Ovid Therapeutics to Present at Two Investor Healthcare Conferences in September 2018 |
| Aug 23 |
FDA OKs new treatment for Dravet syndrome |
| Aug 16 |
Ovid Therapeutics Announces Phase 2 STARS Topline Data Accepted for Presentation at American Academy of Child And Adolescent Psychiatry Annual Meeting |
| Aug 9 |
Ovid Therapeutics beats by $0.07 |
| Aug 9 |
Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress |
| Aug 7 |
Ovid Therapeutics (OVID) OV101 Phase 2 Trial Data - Slideshow |
| Aug 7 |
52 Biggest Movers From Yesterday |
